Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC
Author:
Funder
Key Research and Development Program of Jiangxi Province
National Natural Science Foundation of China
Natural Science Foundation of Jiangxi Province
Publisher
Elsevier BV
Subject
Pharmacology
Reference38 articles.
1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int. J. Cancer,2019
2. Targeted therapies for non-small cell lung cancer;Dempke;Lung Cancer,2010
3. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer;Vasconcellos;Cochrane Database Syst. Rev.,2020
4. Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer;Wu;J. Thorac. Oncol.,2018
5. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer;Greenhalgh;Cochrane Database Syst. Rev.,2016
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The prognostic effect of sixteen malnutrition/inflammation-based indicators on the overall survival of chemotherapy patients;Frontiers in Immunology;2023-02-16
2. Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC;Scientific Reports;2022-08-08
3. Platelet‑to‑lymphocyte and neutrophil‑to‑lymphocyte ratios are associated with the efficacy of immunotherapy in stage III/IV non‑small cell lung cancer;Oncology Letters;2022-06-17
4. Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer;Frontiers in Immunology;2022-04-20
5. The Hippo Signaling Core Components YAP and TAZ as New Prognostic Factors in Lung Cancer;Frontiers in Surgery;2022-03-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3